IHH Healthcare invests Us$20mil in Lucence

KUALA LUMPUR: A leading premium global healthcare provider, IHH Healthcare (IHH), has invested Us$20mil in Series A funding in Singapore-based genomic medicine company Lucence.

The investment is part of IHH’S collaboration with start-ups to deploy innovative and cutting-edge healthcare technology to enhance the patient experience, treatment and clinical outcomes across its network of 80 hospitals in 10 countries.

IHH Healthcare chief executive officer (designate) Dr Kelvin Loh said the investment in Lucence would provide IHH patients with better access to this advanced technology.

“IHH looks to drive greater synergies with Lucence and co-develop solutions for patients, as well as explore opportunities to sharpen our precision medicine capabilities with other like-minded partners across our 10-country network,” he said in a statement yesterday.

Meanwhile, Lucence founder and chief executive officer Dr Min-han Tan said the partnership would give IHH patients access to Lucence’s suite of cancer diagnostics and Artificial Intelligence (Ai)-driven analytics.

“Our research discoveries, such as the identification of the circulating tumour-endothelial cluster, can transform the liquid biopsy field, allowing better non-invasive cancer screening and profiling for patients.

“This partnership with IHH Healthcare will accelerate more groundbreaking research to achieve early cancer detection and effective cures, and expand access to this much-needed liquid biopsy technology to patients across Asia and the United States,” he said.